BioSpace News Archive

LAVA Therapeutics N.V. today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023.

TransMed7, LLC announced today that the “First in Human” series of clinical cases using commercial production Concorde US devices.

NeoGenomics, Inc. announced today that it plans to release its fourth quarter and full year 2022, financial results on Thursday, February 23, 2023.

Inozyme Pharma, Inc. today announced that it will host an Investor and Analyst Event on Thursday, Feb. 16, 2023 at 8 a.m. ET.

Actinium Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes for Health (NIH), to develop Actimab-A for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.

Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that the Company will present additional data from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC, a novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia, during an oral presentation at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), on February 10, 2023.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Monday, March 6th, 2023.

Atreca, Inc. (Atreca) (NASDAQ: BCEL) and Xencor, Inc. (NASDAQ: XNCR) today announced, as part of their existing strategic collaboration, they have mutually selected the first program combining an Atreca-discovered antibody with Xencor’s XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).

LynxDx, Inc. is introducing MyProstateScore 2.0, a non-invasive, data-driven, urine prostate cancer screening test that provides highly accurate, stratified risk assessment insights to guide clinical decisions for patients with elevated prostate-specific antigen or abnormal digital rectal exam findings.

The Glioblastoma Research Organization is proud to announce the appointment of Lance Kawaguchi as its new chairman of the board.